Short answer
ClearPoint Neuro, Inc. (CLPT) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $12M (up 36.3% year over year) with net income of −$7M.
Q3 2026 key financials · XBRL
- Revenue
- $12M
- +36.3% YoY · +11.0% QoQ
- Net income
- −$7M
- −26.6% YoY · +34.2% QoQ
- Operating margin
- -52.4%
- Gross margin
- 58.5%
- EPS (diluted)
- −$0.24
- −14.3% YoY · +36.8% QoQ
Source: XBRL data from the ClearPoint Neuro, Inc. (CLPT) Q3 2026 10-Q on SEC EDGAR. USD.
ClearPoint Neuro, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $12.1M, up 36% YoY from $8.9M
- Gross margin 58% vs 63% YoY, with gross profit $7.1M vs $5.6M
- Best segment: neurosurgery navigation and therapy revenue $5.4M, up 59% YoY
- Worst segment: biologics disposable products $1.2M, down 8% YoY
- Cash $46.2M; nine-month operating cash use $20.1M, ATM proceeds $22.0M supporting liquidity for at least twelve months
Risk Factors
- New risk: CAL preclinical CRO facility investment, triggered by ongoing build-out and operations
- Operational risk: construction, permitting, equipment, or vendor delays could restrict CAL capacity and service offerings
- Regulatory risk: failure to achieve or maintain GLP compliance could prevent GLP study performance
- Market risk: insufficient customer demand or delayed statements of work could leave CAL underutilized
- Financial risk: CAL lease expires approximately eleven years after final premises delivery, with fixed rent and annual increases
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ClearPoint Neuro, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.